scholarly journals Upstream Regulators and Downstream Effectors of NADPH Oxidases as Novel Therapeutic Targets for Diabetic Kidney Disease

2015 ◽  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Nadph Oxidases ◽  
Diabetic Kidney ◽  
Downstream Effectors ◽  
Upstream Regulators ◽  
Novel Therapeutic

Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease

2019 ◽  
Vol 133 (12) ◽  
pp. 1321-1339 ◽  
Author(s):  
Jia Guo ◽  
Zhangsuo Liu ◽  
Rujun Gong
Keyword(s):  
Kidney Disease ◽  
Noncoding Rna ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Developed Countries ◽  
Mechanisms Of Action ◽  
Renal Diseases ◽  
Diabetic Kidney ◽  
Definitive Therapy ◽  
Novel Therapeutic

AbstractDiabetic kidney disease (DKD) is among the most common complications of diabetes mellitus (DM), and remains the leading cause of end-stage renal diseases (ESRDs) in developed countries, with no definitive therapy yet available. It is imperative to decipher the exact mechanisms underlying DKD and identify novel therapeutic targets. Burgeoning evidence indicates that long non-coding RNAs (lncRNAs) are essential for diverse biological processes. However, their roles and the mechanisms of action remain to be defined in disease conditions like diabetes and DKD. The pathogenesis of DKD is twofold, so is the principle of treatments. As the underlying disease, diabetes per se is the root cause of DKD and thus a primary focus of therapy. Meanwhile, aberrant molecular signaling in kidney parenchymal cells and inflammatory cells may directly contribute to DKD. Evidence suggests that a number of lncRNAs are centrally involved in development and progression of DKD either via direct pathogenic roles or as indirect mediators of some nephropathic pathways, like TGF-β1, NF-κB, STAT3 and GSK-3β signaling. Some lncRNAs are thus likely to serve as biomarkers for early diagnosis or prognosis of DKD or as therapeutic targets for slowing progression or even inducing regression of established DKD. Here, we elaborated the latest evidence in support of lncRNAs as a key player in DKD. In an attempt to strengthen our understanding of the pathogenesis of DKD, and to envisage novel therapeutic strategies based on targeting lncRNAs, we also delineated the potential mechanisms of action as well as the efficacy of targeting lncRNA in preclinical models of DKD.

Novel therapeutic agents for the treatment of diabetic kidney disease

2020 ◽  
Vol 29 (11) ◽  
pp. 1277-1293
Author(s):  
Rachel E. Hartman ◽  
P.S.S. Rao ◽  
Mariann D. Churchwell ◽  
Susan J. Lewis
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Agents ◽  
Diabetic Kidney ◽  
Novel Therapeutic

scholarly journals Interplay between RNA-binding protein HuR and Nox4 as a novel therapeutic target in diabetic kidney disease

2020 ◽  
Vol 36 ◽  
pp. 100968 ◽  
Author(s):  
Qian Shi ◽  
Doug-Yoon Lee ◽  
Denis Féliers ◽  
Hanna E. Abboud ◽  
Manzoor A. Bhat ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Therapeutic Target ◽  
Diabetic Kidney Disease ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Diabetic Kidney ◽  
Novel Therapeutic

scholarly journals Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease

2020 ◽  
Vol 21 (11) ◽  
pp. 4113
Author(s):  
Julio M. Martinez-Moreno ◽  
Miguel Fontecha-Barriuso ◽  
Diego Martin-Sanchez ◽  
Juan Guerrero-Mauvecin ◽  
Elena Goma-Garces ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Epigenetic Regulation ◽  
Diabetic Kidney Disease ◽  
Molecular Mechanisms ◽  
Therapeutic Targets ◽  
Sglt2 Inhibitors ◽  
Post Translational Modifications ◽  
Diabetic Kidney ◽  
Bet Inhibitor

Diabetic kidney disease is one of the fastest growing causes of death worldwide. Epigenetic regulators control gene expression and are potential therapeutic targets. There is functional interventional evidence for a role of DNA methylation and the histone post-translational modifications—histone methylation, acetylation and crotonylation—in the pathogenesis of kidney disease, including diabetic kidney disease. Readers of epigenetic marks, such as bromodomain and extra terminal (BET) proteins, are also therapeutic targets. Thus, the BD2 selective BET inhibitor apabetalone was the first epigenetic regulator to undergo phase-3 clinical trials in diabetic kidney disease with an endpoint of kidney function. The direct therapeutic modulation of epigenetic features is possible through pharmacological modulators of the specific enzymes involved and through the therapeutic use of the required substrates. Of further interest is the characterization of potential indirect effects of nephroprotective drugs on epigenetic regulation. Thus, SGLT2 inhibitors increase the circulating and tissue levels of β-hydroxybutyrate, a molecule that generates a specific histone modification, β-hydroxybutyrylation, which has been associated with the beneficial health effects of fasting. To what extent this impact on epigenetic regulation may underlie or contribute to the so-far unclear molecular mechanisms of cardio- and nephroprotection offered by SGLT2 inhibitors merits further in-depth studies.

scholarly journals Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Stephanie Toth-Manikowski ◽  
Mohamed G. Atta
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Renin Angiotensin System ◽  
Current Understanding ◽  
Angiotensin System ◽  
Diabetic Kidney ◽  
Alternative Pathways ◽  
The Past ◽  
The Way

Diabetes is a worldwide epidemic that has led to a rise in diabetic kidney disease (DKD). Over the past two decades, there has been significant clarification of the various pathways implicated in the pathogenesis of DKD. Nonetheless, very little has changed in the way clinicians manage patients with this disorder. Indeed, treatment is primarily centered on controlling hyperglycemia and hypertension and inhibiting the renin-angiotensin system. The purpose of this review is to describe the current understanding of how the hemodynamic, metabolic, inflammatory, and alternative pathways are all entangled in pathogenesis of DKD and detail the various therapeutic targets that may one day play a role in quelling this epidemic.

scholarly journals New Insights into Diabetic Kidney Disease: The Potential Pathogenesis and Therapeutic Targets

2017 ◽  
Vol 2017 ◽  
pp. 1-2 ◽  
Author(s):  
Wei Jing Liu ◽  
Jochen Reiser ◽  
Tae Sun Park ◽  
Zhangsuo Liu ◽  
Shuta Ishibe
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Targets ◽  
Diabetic Kidney
Sign in / Sign up

Export Citation Format

Share Document